Skip to main content
. Author manuscript; available in PMC: 2020 Apr 15.
Published in final edited form as: Clin Cancer Res. 2019 Aug 1;25(20):6080–6088. doi: 10.1158/1078-0432.CCR-19-1135

Table 1.

PD-L1 expression: overall and by IMDC risk groups

METEOR (N=306) CABOSUN (N=110)
N N(%) with PD-L1(+)
(≥1% cutoff for TC and IC)
N N(%) with PD-L1(+)
(≥1% cutoff for TC and IC)
Tumor cells
All patients 306 88(29) 110 25(23)
By IMDC risk groups
 Favorable 64 11(17) - -
 Intermediate 198 58(29) 88 15(17)
 Poor 44 19(43) 22 10(45)
P-value 0.013 0.009
Immune cells
All patients 301 179(59) 110 67(61)
By IMDC risk groups
 Favorable 61 28(46) - -
 Intermediate 196 119(61) 88 50(57)
 Poor 44 32(73) 22 17(77)
P-value 0.019 0.092

IMDC: International Metastatic Renal Cell Carcinoma Database Consortium